Search
Young people transitioning from out-of-home care (OHC) frequently experience poor mental health and resilience due to adverse childhood experiences (ACEs). However, there is limited understanding of the factors that mediate and moderate these outcomes. This is the first study to integrate linked administrative and longitudinal data to examine the mediation and moderation effects of placement stability, independent living skills (ILS), social inclusion, and self-determination when examining the association between ACEs and care status on mental health and resilience.
Among the increasing threats to the healthcare of transgender and gender-diverse people globally, are efforts to deny gender-affirming medical care to people under age 25 typically justified by stating that the human brain is not developed until the mid-to-late 20's. Thus, this line of reasoning states young adults are not sufficiently mature to be responsible for autonomous healthcare decision-making— at least in regard to gender-affirming care.
The widespread use of technology in daily life has raised concerns about its potential to disrupt social relationships, particularly within one of the most important human relationships: the parent-child relationship. This study assesses whether parental social media use (measured by a novel parental social media intensity scale) affects the parent-child relationship (measured by the child-parent relationship scale - short form), and whether parental self-efficacy (PSE, measured by the parenting sense of competence scale) moderates this effect.
Alexithymia is characterised by difficulties identifying and describing feelings, as well as a lack of focus on feelings. Alexithymia is a transdiagnostic risk factor for developing a wide array of psychopathologies, such as anxiety and depression, with a key hypothesised mechanism being the impairing impact of alexithymia on emotion regulation competency. However, no study has tested whether difficulties with emotion regulation mediate the link between alexithymia and psychopathological symptoms using longitudinal designs.
We have read with interest the new publication by Rouhiainen and colleagues on missed opportunities for preventing or diagnosing acute rheumatic fever (ARF).
Clostridioides (Clostridium) difficile transmission between community and healthcare settings has been increasingly reported. We aimed to identify the prevalence and molecular epidemiology of C. difficile colonising adolescents and non-hospitalised children in Cambodia.
Edaravone is used to treat motor neurone disease (MND) by slowing disease progression and prolonging survival time. Currently, it is available as an IV infusion (Radicava®, Jersey City, NJ, USA) and an oral liquid suspension (Radicava ORS®, Jersey City, NJ, USA). Development of novel edaravone formulations is still an active field of research that requires a validated stability-indicating assay capable of providing specific, precise, and accurate quantification of edaravone content.
Human milk bacteria contribute to gut microbiome establishment in breastfed infants. Although breastfeeding is recommended throughout infancy, temporal variation in the milk microbiome-particularly beyond solid food introduction-remains understudied. We analyzed 539 milk samples from 83 mother-infant dyads between 1 week and 12 months postpartum using full-length 16S rRNA gene sequencing.
Rates of several vaccine preventable diseases, and associated hospitalisation, are higher among Aboriginal and/or Torres Strait Islander children than non-Indigenous children. Western Australia has among the lowest childhood vaccine coverage in Australia, particularly among Aboriginal and/or Torres Strait Islander children. Delayed vaccination is also more common in this population. This project aimed to understand the barriers and facilitators to vaccine uptake and timeliness among Aboriginal and/or Torres Strait Islander children aged under five years in Boorloo (Perth).
The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.